2013 Fiscal Year Final Research Report
Characterization and targeting Folate receptor-beta expressed tumor associated macrophages in glioblastoma
| Project/Area Number |
23592134
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
TAKU Nagai 鹿児島大学, 医歯(薬)学総合研究科, 講師 (90363647)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRANO Hirofumi 鹿児島大学, 医学部歯学部附属病院, 講師 (00264416)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | マクロファージ / 脳腫瘍 / 抗体医薬 / イムノトキシン |
|---|
| Research Abstract |
Folate receptor-beta (FRb) is over expressed in tissue-activated macrophages in autoimmune diseases and some tumors (e.g. glioblastoma). We previously determined that FRb-macrophages in glioma may play a role to promote tumor growth.
The present study evaluated the efficacy of targeting of FRb-macrophages by anti-FRb immunotoxin for treating immunotherapy of weakly immunogenic F98 glioma rat models. Fischer rats received an intracerebral implantation of F98 cells. After 3 days, subcutaneous administration of vaccination (freeze/thaw treated F98) were performed in presence/absence of immunotoxin (intraperitoneal administration). However, no significant differences in survival times were observed. When combined liveing cell F98 and immunotoxin administration enhanced survival times, but significance was not observed. We investigated the presence of anti-immunotoxin antibodies. We further developed newly immunotoxin which showed low immunogenicity and used for long-term administration.
|
Research Products
(20 results)
